Cassava Sciences Appoints New Chief Medical Officer
Ticker: FLNA · Form: 8-K · Filed: May 8, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | May 8, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
Related Tickers: SAVA
TL;DR
SAVA names Dr. Newman, ex-Biogen/Pfizer, as CMO to push neurodegenerative drugs.
AI Summary
On May 8, 2024, Cassava Sciences, Inc. filed an 8-K report detailing the appointment of Dr. Eric D. Newman as Chief Medical Officer. Dr. Newman brings extensive experience in neurology and clinical development, previously holding leadership roles at companies like Biogen and Pfizer. His appointment is expected to bolster Cassava's efforts in advancing its neurodegenerative disease treatments.
Why It Matters
The appointment of a new Chief Medical Officer with significant industry experience could signal a renewed focus and strategic direction for Cassava Sciences' drug development pipeline, potentially impacting the future of its neurodegenerative disease therapies.
Risk Assessment
Risk Level: medium — The appointment of a new CMO is a significant leadership change that could impact the company's strategic direction and the success of its drug development programs.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- Dr. Eric D. Newman (person) — Appointed Chief Medical Officer
- Biogen (company) — Previous employer of Dr. Newman
- Pfizer (company) — Previous employer of Dr. Newman
- May 8, 2024 (date) — Date of report
FAQ
What is the effective date of Dr. Eric D. Newman's appointment as Chief Medical Officer?
The filing does not explicitly state an effective date for Dr. Newman's appointment, but it was reported on May 8, 2024.
What previous companies has Dr. Eric D. Newman worked for?
Dr. Newman has held leadership roles at Biogen and Pfizer.
What is Cassava Sciences, Inc.'s primary focus?
Cassava Sciences, Inc. is focused on developing treatments for neurodegenerative diseases.
What is the Standard Industrial Classification code for Cassava Sciences, Inc.?
The SIC code for Cassava Sciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
In which state was Cassava Sciences, Inc. incorporated?
Cassava Sciences, Inc. was incorporated in Delaware.
Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 9.9 · Accepted 2024-05-08 16:05:51
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- f8k_050824.htm (8-K) — 22KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-002669.txt ( ) — 244KB
- sava-20240508.xsd (EX-101.SCH) — 4KB
- sava-20240508_def.xml (EX-101.DEF) — 26KB
- sava-20240508_lab.xml (EX-101.LAB) — 36KB
- sava-20240508_pre.xml (EX-101.PRE) — 25KB
- f8k_050824_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On May 8, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated May 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cassava Sciences, Inc. Date: May 8, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer